Venmax Drugs & Pharmaceuticals Limited (VDPL) has reported a significant increase in revenue and a return to profitability for the quarter ended September 30, 2025. The company also made progress on its proposed amalgamation with Hatri Pharma Private Limited, a move aimed at enhancing operational efficiencies and achieving economies of scale.

Financial Performance

VDPL's financial results for Q2 FY2026 show substantial improvement compared to the same period last year:

For the half-year ended September 30, 2025, the company's revenue reached Rs 252.87 lakhs, compared to Rs 27.53 lakhs in the previous year, marking a significant year-over-year growth of 818.9%.

Amalgamation Progress

The Board of Directors approved the financial statements as of September 30, 2025, for valuation purposes related to the proposed amalgamation with Hatri Pharma Private Limited. This follows the initial approval of the amalgamation on September 2, 2025.

Key details of the amalgamation include:

1. Share Exchange Ratio: Shareholders of Hatri Pharma will receive 1 equity share of Venmax for every 1 share held in Hatri Pharma.
2. Company Profiles:
   • Hatri Pharma: Net worth of Rs 1,610 lakhs and turnover of Rs 1,846.41 lakhs
   • Venmax Drugs: Net worth of Rs 857.72 lakhs and turnover of Rs 252.87 lakhs

Rationale for Amalgamation

The amalgamation aims to achieve several strategic objectives:

1. Operational and administrative efficiencies
2. Optimal utilization of infrastructure and resources
3. Cost reduction through focused operational efforts
4. Backward integration to enhance efficiencies and achieve economies of scale
5. Streamlined legal and regulatory compliance
6. Adoption of best practices and enhanced automation

Financial Position

As of September 30, 2025, Venmax Drugs reported:

• Total Assets: Rs 1,364.68 lakhs (up from Rs 516.96 lakhs on March 31, 2025)
• Total Equity: Rs 857.72 lakhs (increased from Rs 441.19 lakhs)
• Cash and Cash Equivalents: Rs 562.26 lakhs (significant increase from Rs 248.24 lakhs)

The company's improved financial position and cash flow appear to support its growth initiatives and the proposed amalgamation.

Outlook

With the strong revenue growth and return to profitability, coupled with the strategic move towards amalgamation, Venmax Drugs & Pharmaceuticals Limited appears to be positioning itself for further growth in the pharmaceutical sector. The successful completion of the amalgamation with Hatri Pharma Private Limited could potentially strengthen the company's market position and operational capabilities in the coming years.

Venmax Drugs & Pharmaceuticals Limited , a pharmaceutical company based in Hyderabad, has announced its unaudited standalone financial results for the quarter ended June 30, showcasing a significant improvement in its performance.

Financial Highlights

The company reported revenue from operations of Rs 121.03 lakhs for the quarter. Venmax Drugs & Pharmaceuticals achieved a profit of Rs 3.74 lakhs, demonstrating a positive financial outcome.

Key Financial Metrics

Operational Performance

The company's total expenses for the quarter stood at Rs 117.29 lakhs. The total revenue, including other income, reached Rs 121.03 lakhs.

Balance Sheet Strength

Venmax Drugs & Pharmaceuticals' balance sheet showed improvements in key areas:

• Cash and cash equivalents increased to Rs 251.94 lakhs from Rs 248.24 lakhs in the previous quarter.
• Trade receivables rose significantly to Rs 230.81 lakhs from Rs 95.26 lakhs, suggesting improved sales and potential market expansion.

Management Commentary

The financial results were approved by the Board of Directors. The statutory auditors, PPKG & Co Chartered Accountants, have carried out a limited review of the standalone financial results.

Venmax Drugs & Pharmaceuticals Limited's performance in this quarter suggests a positive trajectory, with growth in revenue and profitability.